Insider Transactions in Q1 2025 at X4 Pharmaceuticals, Inc (XFOR)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 24
2025
|
Christophe Arbet Engels Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
11,624
-45.0%
|
$0
$0.45 P/Share
|
|
Jan 24
2025
|
Mary Di Biase Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
22,258
-4.34%
|
$0
$0.45 P/Share
|
|
Jan 24
2025
|
Mark Baldry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
29,159
-23.65%
|
$0
$0.45 P/Share
|
|
Jan 24
2025
|
Adam S. Mostafa Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
74,773
-100.0%
|
$0
$0.45 P/Share
|
|
Jan 24
2025
|
Paula Ragan President and CEO |
SELL
Open market or private sale
|
Direct |
76,473
-6.57%
|
$0
$0.45 P/Share
|
|
Jan 23
2025
|
Christophe Arbet Engels Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
25,831
+50.0%
|
-
|
|
Jan 23
2025
|
Mary Di Biase Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
61,178
+10.65%
|
-
|
|
Jan 23
2025
|
Mark Baldry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,773
+37.75%
|
-
|
|
Jan 23
2025
|
Adam S. Mostafa Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
74,773
+50.0%
|
-
|
|
Jan 23
2025
|
Paula Ragan President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
169,940
+12.74%
|
-
|